Europe Galacto-oligosaccharide Market

Europe Galacto-oligosaccharide Market Size

The Europe Galacto-oligosaccharide Market size was calculated to be worth USD 0.95 billion in 2025 and is anticipated to be worth USD 1.76 billion by 2034, from USD 1.02 billion in 2026, growing at a CAGR of 7.07% during the forecast period.

Galacto-oligosaccharides (GOS) are non-digestible prebiotic carbohydrates synthesized from lactose, primarily used to modulate gut microbiota by stimulating the growth of beneficial bacteria such as Bifidobacteria and Lactobacilli. In Europe, GOS is widely incorporated into infant formula, functional dairy products, dietary supplements, and clinical nutrition solutions due to its well-documented role in digestive health, immune modulation, and mineral absorption. According to the European Food Safety Authority, GOS has received a positive scientific opinion confirming its safety and efficacy for use in infant formula at concentrations up to 0.8 grams per 100 millilitres. According to Eurostat, the European Union records several million births annually, supporting sustained baseline demand for GOS‑fortified infant nutrition. As per the European Commission’s Register of Nutrition and Health Claims, GOS is one of only two prebiotics authorized for use in infant formula across all EU member states. Additionally, national dietary surveys in Germany and the Netherlands indicate that 38% of adults actively consume prebiotic‑enriched foods weekly, which reflects growing consumer awareness of gut health. This regulatory endorsement, combined with rising scientific validation and demographic demand, positions GOS as a cornerstone of Europe’s functional food and clinical nutrition landscape.

MARKET DRIVERS

Mandatory Inclusion of Prebiotics in Infant Formula Across EU Member States

The regulatory framework governing infant formula in Europe continues to drive stable demand for galacto‑oligosaccharides, as prebiotics are widely permitted and incorporated to help mimic the functional properties of human milk, which is one of the major factors driving the European galacto‑oligosaccharides market. Following the European Commission’s amendment to Directive 2006/141/EC, infant‑formula manufacturers may add galacto‑oligosaccharides and fructo‑oligosaccharides in defined ratios to support the growth of beneficial gut bacteria. According to the European Food Safety Authority, multiple clinical studies show that GOS supplementation increases fecal Bifidobacteria and improves stool consistency in infants, supporting its inclusion in formula. Product‑label audits by the European Consumer Organisation confirm that GOS is present in the majority of standard infant‑formula products sold across major EU markets, reflecting widespread industry adoption. National guidance reinforces this trend as the UK Scientific Advisory Committee on Nutrition acknowledges the role of prebiotics in infant feeding. With more than four million births annually in the EU, and formula serving as the primary alternative for non‑breastfed infants, GOS benefits from a structurally stable demand base.

Rising Scientific Endorsement of GOS for Gut-Immune Axis Modulation in Adults

Growing scientific evidence linking galacto‑oligosaccharides to immune and gut‑health benefits is expanding its use beyond infant nutrition into adult functional foods and medical nutrition, which is further contributing to the regional market expansion. According to a 2022 review published in the European Journal of Nutrition, GOS intake has been associated with increases in beneficial gut bacteria and improvements in markers of immune function in adults. This aligns with rising consumer interest in immunity‑supportive foods across Europe. As per the European Food Safety Authority’s consumer insights, a significant proportion of EU adults actively seek foods that support digestive and immune health, reflecting post‑pandemic priorities. National health bodies are also taking note as the French Agency for Food Safety has highlighted prebiotic fibres, including GOS, as supportive components for maintaining gut microbiota balance in older adults. Clinical‑nutrition providers such as Nutricia and Fresenius Kabi incorporate GOS into enteral formulas to help mitigate dysbiosis in vulnerable patients, further broadening its application.

MARKET RESTRAINTS

Stringent EU Novel Food and Health Claim Authorization Processes

The European galacto‑oligosaccharide market faces regulatory constraints due to the EU’s strict health‑claim and novel‑food authorization processes, which limit marketing flexibility. Although GOS is permitted in infant formula, any new health claim for general‑population foods must undergo full evaluation under Regulation (EC) 1924/2006. According to the European Commission’s EU Register of Nutrition and Health Claims, only a small number of prebiotics‑related claims have been authorized, and none apply broadly to adult GOS‑fortified foods. This restricts brands from making explicit benefit statements, forcing reliance on general terms such as digestive support. As per EFSA’s published timelines, health‑claim dossiers typically require more than one year for evaluation, creating cost and uncertainty for manufacturers. These regulatory hurdles discourage smaller companies from pursuing claim substantiation and limit innovation in functional‑food positioning.

Consumer Confusion Between Prebiotics, Probiotics,s and Synbiotics

Consumer misunderstanding of prebiotic functionality remains a major barrier to wider adoption of galacto‑oligosaccharides in adult nutrition. According to the European Consumer Organisation, many EU consumers struggle to distinguish between prebiotics and probiotics, often assuming both refer to live bacteria rather than recognizing prebiotics as fermentable fibres that nourish beneficial microbes. This confusion affects purchasing behaviour, with shoppers frequently choosing probiotic products even when prebiotic options may offer greater stability or shelf‑life advantages. Retail merchandising practices contribute to the issue, as GOS‑fortified products are often shelved alongside probiotics without clear differentiation. The absence of standardized front‑of‑pack labeling for prebiotic content further limits consumer understanding. These knowledge gaps reduce the visibility of GOS benefits and hinder its expansion into adult functional‑food categories where informed choice is essential.

MARKET OPPORTUNITIES

Expansion of GOS into Medical Nutrition for the Elderly and Clinical Populations

A high‑value opportunity for galacto‑oligosaccharides lies in their integration into medical‑nutrition products targeting Europe’s aging population and patients with chronic gastrointestinal conditions. According to Eurostat, 21.3% of the EU population was aged 65 or older in 2025, increasing the prevalence of age‑related declines in Bifidobacteria abundance and the need for prebiotic support. Scientific evidence reinforces this application as multiple clinical studies reviewed by the European Food Safety Authority show that GOS supplementation improves bowel regularity and supports beneficial gut microbiota in older adults. Medical‑nutrition companies have responded accordingly. Fresenius Kabi has introduced GOS‑enriched enteral formulas for geriatric care in several EU markets, while Nestlé Health Science includes GOS in formulations designed for digestive‑health management. Reimbursement pathways further support adoptionas as per the European Federation of Pharmaceutical Industries and Associations, medical foods containing prebiotic fibres are eligible for reimbursement in several EU member states when prescribed for malnutrition or post‑hospitalization recovery.

Development of Sustainable GOS Production from Dairy Byproducts

A major opportunity for galacto‑oligosaccharides stems from Europe’s circular‑bioeconomy goals, particularly the valorisation of lactose‑rich dairy permeates. Traditionally considered a low‑value byproduct of cheese and casein production, whey permeate is now widely used as the primary feedstock for enzymatic GOS synthesis. According to the European Dairy Association, the EU generates more than 12 million tons of whey permeate annually, much of which historically lacked high‑value applications. Companies such as FrieslandCampina and Arla Foods have invested in biorefinery systems that convert permeate into GOS, supporting waste reduction and resource efficiency. Life‑cycle assessments conducted by Wageningen University show that GOS produced from dairy permeate has a substantially lower carbon footprint compared with chemically synthesized prebiotics, aligning with the European Commission’s Farm to Fork Strategy, which prioritizes zero‑waste dairy processing. This approach enhances both environmental performance and economic viability, making permeate‑based GOS attractive to sustainability‑focused brands.

MARKET CHALLENGES

Price Volatility of Dairy‑Derived Lactose Feedstock

A key challenge for the European galacto‑oligosaccharide market is exposure to fluctuations in lactose prices, which are closely tied to dairy‑market dynamics. As GOS is enzymatically synthesized from lactose, production costs rise when dairy supply tightens. According to the European Commission’s Dairy Market Observatory, EU lactose prices experienced significant volatility in 2023–2025, driven by shifts in cheese production, export demand, and milk‑supply constraints. This instability compresses margins for GOS manufacturers, particularly smaller producers lacking long‑term supply contracts. Industry associations report that many processors introduced surcharge clauses in 2025 to offset feedstock‑price risk. Some manufacturers have also prioritized infant‑formula contracts—where pricing is more stable—over discretionary adult‑nutrition applications. Until lactose sourcing is stabilized through vertical integration or alternative non‑dairy feedstocks, GOS pricing and supply reliability will remain vulnerable to broader agricultural‑market fluctuations.

Limited Efficacy Data for GOS in Non‑Infant Pediatric Populations

Despite strong evidence supporting GOS use in infants, the market faces a scientific gap in older pediatric populations, which is limiting expansion into toddler and children’s nutrition and further challenging the regional market growth. European parents increasingly seek gut‑health solutions for issues such as constipation and recurrent infections, yet clinical validation for GOS in children over 12 months remains limited. According to the European Society for Paediatric Gastroenterology, only a small number of randomized controlled trials have evaluated GOS in children aged 1–10, compared with extensive evidence in infants. This lack of data prevents health‑claim authorizationas the European Food Safety Authority has not approved any GOS‑related claims for toddler or children’s products. As a result, major brands such as HiPP and Holle rely on alternative fiber blends with clearer regulatory pathways. Surveys of European parents consistently show a strong interest in prebiotic‑fortified children’s products, but without targeted clinical research, GOS adoption in this segment remains constrained.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The powder segment dominated the market by accounting for 74.4% of the European market share in 2025. The leading position of pothe wder segment in the European market is primarily due to its superior stability, ease of formulation, and compatibility with dry‑mix applications such as infant formula and dietary supplements. Powdered GOS exhibits a shelf life of up to 24 months under ambient conditions, making it logistically advantageous for large‑scale manufacturing and long‑distance distribution across the EU. According to the European Commission’s infant‑nutrition regulatory framework, stability testing protocols for prebiotic content are standardized for dry matrices, which supports the widespread use of powder formats. Powder GOS also integrates seamlessly into automated production lines where moisture‑sensitive ingredients are handled, which is critical in facilities producing hypoallergenic or low‑moisture nutritional powders. In Europe’s infant‑formula sector, powder remains the preferred form due to precise dosing accuracy and resistance to microbial degradation during storage. Shelf‑stable adult supplements also rely heavily on powder formats for formulation consistency. Powder GOS is expected to maintain its dominance over the forecast period as dry‑mix nutrition products continue to expand across Europe.

The syrup segment is the fastest-growing form of galacto‑oligosaccharide in Europe and is anticipated to grow at a CAGR of 8.3% over the forecast period o, owing to the rising demand for ready‑to‑consume functional beverages and liquid medical‑nutrition products requiring prebiotics in soluble, instantly mixable formats. According to the European Food Safety Authority, GOS syrup maintains stability across beverage‑relevant pH ranges, supporting its use in acidic drinks such as kombucha and fruit‑based beverages. Syrup’s liquid nature also supports clean‑label formulation by eliminating the need for additional solubilizers or high‑shear mixing. In clinical settings, liquid enteral formulas enriched with GOS syrup are increasingly used due to easier tube‑feeding compatibility for elderly and clinical‑nutrition patients. The format is also gaining traction in children’s wellness drinks and plant‑based beverages. Syrup GOS is expected to grow rapidly over the forecast period as liquid functional‑nutrition categories expand across Europe.

By Application Insights

The food and beverages segment had the most dominating share of the European market in 2025 due to the mandatory integration of GOS into infant formula across all EU member states, which alone consumes a substantial share of total GOS volume. According to Eurostat, the EU records more than 4 million annual births, creating structurally strong demand for infant‑nutrition ingredients. Beyond infant formula, GOS is increasingly incorporated into functional dairy products such as yogurts, fermented milks, and growing‑up milks. As per the European Dairy Association, prebiotic enrichment is a growing trend in dairy formulations, with GOS favored due to its neutral taste and regulatory approval. National dietary guidelines in several EU countries also support the use of prebiotic‑fortified dairy for early‑childhood nutrition. Food and beverages are expected to remain the dominant application segment over the forecast period as infant nutrition and functional dairy categories continue to expand.

The dietary‑supplements segment is the fastest-growing application for galacto‑oligosaccharides in Europe and is expected to witness a CAGR of 10.8% over the forecast period. This surge reflects escalating consumer interest in targeted gut‑health solutions beyond general wellness, particularly among adults seeking microbiome balance for immunity, mental well‑being, and digestive regularity. According to the European Commission’s consumer‑health monitoring, prebiotic supplement usage has risen significantly across major EU markets, driven by heightened awareness of microbiome science. Regulatory developments have also enabled growth: the European Commission’s clarification on novel‑food compliance for GOS in capsules and tablets has supported broader supplement‑category adoption. Clinical validation is accelerating uptake as well. As per a 2025 University of Copenhagen study, daily GOS intake significantly increases beneficial Bifidobacteria levels in adults, reinforcing its functional value. Dietary supplements are expected to grow strongly over the forecast period as microbiome‑focused nutrition becomes mainstream across Europe.

REGIONAL ANALYSIS

Germany Galacto-Oligosaccharide Market Analysis

Germany dominated the galacto‑oligosaccharide market in Europe with a 24.1% share in 2025. The dominance of Germany in the European market is driven by the strong infant‑formula manufacturing base and the advanced medical‑nutrition sector. According to the German Federal Statistical Office, national birth figures continue to sustain steady demand for GOS‑fortified formula, while the country’s extensive elder‑care network reinforces clinical‑nutrition usage. Germany also hosts major producers that operate dedicated GOS processing and formulation facilities, strengthening domestic supply capabilities. The Federal Institute for Risk Assessment provides clear regulatory guidance for prebiotic use, supporting industry confidence and compliance. The German Nutrition Society’s updated dietary recommendations highlight the role of prebiotics in gut health, reinforcing consumer acceptance across age groups. With its combination of demographic scale, manufacturing depth, and scientific endorsement, Germany is expected to remain Europe’s most influential GOS market.

Netherlands Galacto-Oligosaccharide Market Analysis

The Netherlands held the second-largest share of the European GOS market in 2025. The growth of the Netherlands in the European market is driven by its integrated dairy‑processing ecosystem and strong export orientation. The country’s major dairy cooperatives leverage whey‑based byproducts to produce high‑purity GOS, aligning with national circular‑economy priorities. The Netherlands also serves as a major infant‑formula export hub, supplying GOS‑fortified products to multiple European regions. The Netherlands Nutrition Centre continues to promote prebiotics in early‑life nutrition, supporting domestic demand. Dutch consumers demonstrate high awareness of gut‑health ingredients, contributing to strong acceptance of GOS‑containing products. With its combination of sustainable production, scientific alignment, and export strength, the Netherlands is positioned to maintain a central role in Europe’s GOS supply chain.

France Galacto-Oligosaccharide Market Analysis

France is estimated to showcase a promising CAGR in the European GOS market over the Forecast period. The premium infant‑nutrition culture and strong regulatory framework are propelling the French market growth. French parents show a high willingness to purchase scientifically validated formulas, making GOS inclusion a standard expectation. Santé Publique France reports widespread use of prebiotics in infant‑formula formulations, often paired with complementary fibers to mimic natural composition. The French Agency for Food Safety maintains active oversight of prebiotic applications, enabling timely approval of new uses in medical‑nutrition products. France’s expanding clinical‑nutrition sector incorporates GOS into enteral formulas for various patient groups. Ongoing research funded by national agricultural institutes continues to explore GOS benefits in mineral absorption and digestive health. With its blend of scientific rigor and premium consumer expectations, France is likely to retain its strong market position.

United Kingdom Galacto-Oligosaccharide Market Analysis

The United Kingdom is estimated to hold a prominent share of the European GOS market during the forecast period o, owing to the rapid supplement innovation and flexible post‑Brexit regulatory pathways. The UK Food Standards Agency has registered a growing number of GOS‑based supplements under the novel‑food framework, benefiting from streamlined evaluation timelines. Domestic brands have introduced high‑dose GOS formulations targeting digestive and cognitive‑wellness trends. The National Health Service includes GOS‑fortified formulas within its infant‑feeding guidance, ensuring stable baseline demand. UK universities continue to lead microbiome research, generating clinical insights that support product development. With its combination of regulatory agility, scientific leadership, and strong consumer interest in functional supplements, the UK is expected to remain a high‑growth innovation hub.

Italy Galacto-Oligosaccharide Market Analysis

Italy is projected to account for a noteworthy share of the European GOS market during the forecast period due to its strong dairy tradition and emphasis on pediatric nutrition. According to ISTAT, national birth figures continue to support demand for GOS‑fortified formula and growing‑up milks. Major dairy cooperatives incorporate GOS into premium children’s products, reinforcing its role in early‑life nutrition. The Italian Ministry of Health permits GOS use in medical foods for digestive sensitivities, expanding its clinical relevance. Interest in functional fermented beverages is rising, with GOS‑enriched options gaining traction in southern regions. Research from national scientific institutions continues to explore prebiotic benefits in adolescent nutrition, strengthening scientific credibility. With its combination of demographic demand and food‑culture alignment, Italy is positioned for steady, long‑term GOS consumption.

COMPETITION OVERVIEW

The Europe galacto-oligosaccharide market features focused competition among a handful of large dairy-integrated and specialty ingredient companies with strong scientific and regulatory capabilities. Unlike consumer-driven markets, competition here is determined by technical excellence f, formulation support, nd compliance assurance rather than branding or pricing. Barriers to entry are high due to the need for enzymatic expertise d, processing infrastructure, and extensive safety dossiers required under EU novel food and infant formula regulations. The market is segmented into two tiers: global dairy giants like FrieslandCampina and DSM-Firmenich dominate the large volume infant nutrition supply, while specialized players such as Nordic Pharma target high-margin medical and clinical segments. Differentiation arises from purity levelsolubilitytyy profiles, nd clinical validation depth rather than product novelty. Collaboration with research institutions and health authorities is common, reflecting the market’s science-intensive nature. As gut health gains broader recognition, competition is gradually expanding into adult supplements and functional beverages, but infant formula remains the anchor that shapes investment and innovation priorities across the sector.

KEY MARKET PLAYERS

A few major players of the Europe galacto-oligosaccharide market include

• Friesland Campina
• Yakult Pharmaceutical Industry Co., Ltd
• Quantum Hi-Tech Biological Co., Ltd
• Ingredion Incorporated
• Nissin Sugar Co., Ltd
• New Francisco Biotechnology Corporation. Ltd
• Samyang Food Co., Ltd
• Baolingbao Biology Co., Ltd

Top Strategies Used by the Key Market Participants

Key players in the Europe galacto-oligosaccharide market prioritize vertical integration by sourcing lactose from their own dairy operations to ensure feedstock security and cost stability. They invest in clinical research to expand evidence for GOS in adult and pediatric populations beyond infancy, supporting new health claims and applications. Companies develop both powder and syrup formats to address diverse formulation needs across infant formula, functional food,s and medical nutrition. Sustainability is emphasized through circular production models that convert whey permeate into high-value prebiotics. Regulatory engagement remains critical as firms work closely with the European Food Safety Authority to maintain compliance and anticipate novel food requirements. These strategies collectively enhance scientific credibility, supply resilience, and market adaptability in a highly regulated nutritional ingredients landscape.

Leading Players in the Europe Galacto-Oligosaccharide Market

• FrieslandCampina Ingredients is a leading producer of galacto-oligosaccharides in Europe, leveraging its integrated dairy supply chain to manufacture high-purity GOS from whey permeate at its facilities in the Netherlands and Germany. The company supplies both powder and syrup formats to infant formula manufacturers, medical nutrition companies, and functional food brands across the continent. In 2025, FrieslandCampina launched a next-generation OS syrup with enhanced solubility for acidic beverage applications and expanded its clinical dossier with new data on GOS and immune modulation in elderly populations. It also reinforced its sustainability credentials by achieving zero-waste-to-landfill status at its GOS production site in Amersfoort. These actions strengthen its position as a science-driven, vertically integrated partner in Europe’s prebiotic ecosystem while supporting its global supply commitments to Asia and North America.
• DSM-Firmenich plays a pivotal role in the Europe galacto-oligosaccharide market through its premium Biotis GOS portfolio, which is widely used in infant nutrition and medical foods. The company combines advanced enzymatic synthesis with rigorous quality control to deliver GOS with consistent purity and functionality. In 2025, DSM-Firmenich deepened its collaboration with European pediatric research centers to generate real-world evidence on GOS efficacy in toddler nutrition and launched a clean-label GOS powder tailored for organic infant formula compliance. It also integrated GOS into its gut-brain axis solutions for adult supplements, aligning with emerging wellness trends. By anchoring innovation in clinical science and regulatory expertise, DSM-Firmenich maintains its reputation as a trusted ingredient partner for high-value applications across Europe and globally.
• Nordic Pharma Group has established a distinctive presence in the Europe galacto-oligosaccharide market by focusing on clinical and pharmaceutical-grade GOS for medical nutrition and therapeutic applications. The company supplies GOS to enteral formula producers and hospital nutrition providers in Scandinavia, Germany, and the UK, emphasizing traceability, batch consistency, and regulatory compliance. In 2025, Nordic Pharma initiated a multicenter study in Sweden and Denmark to evaluate GOS in reducing antibiotic-associated diarrhea in geriatric patients and introduced a GMP-certified GOS syrup for compounding pharmacies. It also enhanced its digital ordering platform with real-time regulatory documentation for EU medical device and food compliance. This clinical orientation and commitment to pharmaceutical standards differentiate Nordic Pharma in a market increasingly focused on evidence-based health outcomes.

MARKET SEGMENTATION

This research report on the Europe galacto-oligosaccharide market has been segmented and sub-segmented based on product, application, and region.

By Product

• Powder
• Syrup

By Application

• Food & Beverages
• Dietary Supplements

By Region

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe